Exonate closes second successful funding round

Early stage biotechnology company targeting ophthalmology and potentially pain and cancer Funding to develop treatment for wet age-related macular degeneration (wet AMD) Cambridge, UK, Monday 5th October 2015 – Exonate, an early stage biotechnology company, today announced they have successfully closed their latest funding round including investment from the Angel CoFund. This brings the total…